Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 14, 2021 07:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency at ESGCT

PITTSBURGH, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present...
October 01, 2021 16:01 ET | Source: Krystal Biotech, Inc.

Krystal Biotech to Present at the Chardan 5th Annual Genetic Medicines Conference

PITTSBURGH, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced its participation in the...
September 29, 2021 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Receives Approval from the Human Research Ethics Committee in Australia for Phase 1 Trial of KB407 for Cystic Fibrosis

- KB407 is an investigational inhaled gene therapy derived from Krystal’s clinically validated redosable gene delivery technology platform PITTSBURGH, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Krystal...
September 15, 2021 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Appoints Laurent Goux as General Manager of Europe

PITTSBURGH, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced the appointment of Laurent...
September 09, 2021 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021

Data include evaluation of investigational B-VEC in a murine corneal wound modelU.S. FDA has recently approved a compassionate use request for topical B-VEC application to one eye in a RDEB patient ...
September 07, 2021 16:31 ET | Source: Krystal Biotech, Inc.

Krystal Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

PITTSBURGH, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced it will be featured as a...
August 09, 2021 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Reports Second Quarter 2021 Financial Results and Provides Update on Operational Progress

Top-line data from the pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (“DEB”) on track for 4Q21Initiation of Phase 1 study of inhaled KB407 for the treatment of cystic fibrosis...
July 01, 2021 16:15 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of TGM-1 Associated Ichthyosis

- New data include update from the fourth patient treated in the Phase 1/2 trial - Repeat topical KB105 dosing continues to be well tolerated with no adverse events or evidence of immune response ...
June 03, 2021 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech to Participate in Upcoming Investor Conferences

PITTSBURGH, June 03, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced participation in two...
May 10, 2021 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Reports First Quarter 2021 Financial Results and Provides Update on Operational Progress

Completed enrollment in pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (DEB) Strong balance sheet with March 31, 2021 cash, cash equivalents and short-term investments of $403.4...